# Michael Hallek

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-hallek/

## Facts

| Field | Value |
| --- | --- |
| Citations | 72,792 |
| Field | Chronic Lymphocytic Leukemia Research |
| h-index | 126 |
| i10-index | 687 |
| Last Known Institution | University of Cologne |
| OpenAlex ID | https://openalex.org/A5076077834 |
| ORCID iD | https://orcid.org/0000-0002-7425-4455 |
| Works | 1,651 |

## Researcher papers

- [Comprehensive genomic profiles of small cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-profiles-of-small-cell-lung-cancer/)
- [Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/addition-of-rituximab-to-fludarabine-and-cyclophosphamide-in-patients-with/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia](https://scholariq.org/papers/i-tp53-i-mutation-and-survival-in-chronic-lymphocytic-leukemia/)
- [Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial](https://scholariq.org/papers/gene-mutations-and-treatment-outcome-in-chronic-lymphocytic-leukemia-results/)
- [Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-in-combination-with-rituximab-for-previously-untreated-patients/)
- [Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia](https://scholariq.org/papers/requirement-of-src-kinases-lyn-hck-and-fgr-for-bcr-abl1-induced-b-lymphoblastic/)
- [Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group](https://scholariq.org/papers/bendamustine-combined-with-rituximab-in-patients-with-relapsed-and-or-refractory/)
- [Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial](https://scholariq.org/papers/allogeneic-stem-cell-transplantation-provides-durable-disease-control-in-poor/)
- [Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial](https://scholariq.org/papers/detailed-analysis-of-p53-pathway-defects-in-fludarabine-refractory-chronic/)

## Researcher topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)

## Researcher university

- [University of Cologne](https://scholariq.org/institutions/university-of-cologne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.